ArticleTropical medicine and health2026
Sex-specific burdens of acute hepatitis B and C and their attributable risk factors in 204 countries and territories, 1990-2021.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of histologic hepatic steatosis on virological response to nucleos(t)ide analogue therapy in patients with chronic hepatitis B.Medicine · 2026Observational
- Subnational inequalities and preventable gaps in drowning premature mortality and non-fatal health loss among population younger than 20 years.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute hepatitis B (AHB) and acute hepatitis C (AHC) remain major global health challenges despite the World Health Assembly's 2030 elimination goals. In addition, the COVID-19 pandemic has disrupted hepatitis control efforts, and sex-specific differences in disease burden remain underexplored. This study aimed to systematically quantify the temporal, geographic, age-, and sex-specific burden of AHB and AHC, as well as the contribution of drug use to disease burden at the global, regional, and national levels.
methodsUsing data from the Global Burden of Disease Study 2021, we analyzed prevalence, mortality, and disability-adjusted life years (DALYs) for AHB and AHC across 204 countries and 21 regions from 1990 to 2021, with a focus on age, sex, and drug-use-related risk factors.
resultsIn 2021, global AHB and AHC cases reached 7.3 million and 0.8 million, representing respective declines of 40.2% and 10.7% since 1990. Despite overall reductions, significant regional and sex disparities persist. Males exhibited consistently higher burdens, influenced by biological and behavioral factors. The proportion of DALYs attributable to drug use increased for both infections, especially for AHC. Unexpectedly, South Asia showed rising AHB-related DALYs despite socioeconomic improvement.
conclusionsAlthough the global burden of AHB and AHC has declined, persistent disparities highlight the need for tailored, virus-specific strategies. Expanding vaccination, screening, antiviral access, and harm-reduction programs is crucial to achieving viral hepatitis elimination by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.